[Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children].

Q3 Medicine 中国当代儿科杂志 Pub Date : 2024-12-15 DOI:10.7499/j.issn.1008-8830.2406089

Yi-Chen Ma, Xi-Hui Zhou, Xiao-Dan Zhao, Chen-Yang Wang

{"title":"[Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children].","authors":"Yi-Chen Ma, Xi-Hui Zhou, Xiao-Dan Zhao, Chen-Yang Wang","doi":"10.7499/j.issn.1008-8830.2406089","DOIUrl":null,"url":null,"abstract":"Objectives: To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) in children.Methods: A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC. The efficacy and adverse drug reactions were compared between the two groups, and the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP) were analyzed.Results: Compared with the PAZM group, the SDXC group had significantly shorter time to defervescence and time to cough relief, a significantly lower proportion of patients using glucocorticoids, and a significantly higher proportion of patients with lung lesion absorption (P<0.05). No adverse reactions such as liver and kidney function impairment and tooth discoloration were observed in either group. RMPP occurred in 47 cases in the PAZM group. The univariate analysis showed that lactate dehydrogenase levels and age were risk factors for RMPP (P<0.05).Conclusions: The efficacy of SDXC is superior to that of PAZM in children with MUMPP, and short-term use of doxycycline is relatively safe.","PeriodicalId":39792,"journal":{"name":"中国当代儿科杂志","volume":"26 12","pages":"1294-1300"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11684836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国当代儿科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7499/j.issn.1008-8830.2406089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) in children.

Methods: A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC. The efficacy and adverse drug reactions were compared between the two groups, and the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP) were analyzed.

Results: Compared with the PAZM group, the SDXC group had significantly shorter time to defervescence and time to cough relief, a significantly lower proportion of patients using glucocorticoids, and a significantly higher proportion of patients with lung lesion absorption (P<0.05). No adverse reactions such as liver and kidney function impairment and tooth discoloration were observed in either group. RMPP occurred in 47 cases in the PAZM group. The univariate analysis showed that lactate dehydrogenase levels and age were risk factors for RMPP (P<0.05).

Conclusions: The efficacy of SDXC is superior to that of PAZM in children with MUMPP, and short-term use of doxycycline is relatively safe.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[延长阿奇霉素治疗对大环内酯无反应的儿童肺炎支原体肺炎的疗效对比]。

目的：探讨长期阿奇霉素（PAZM）与多西环素（SDXC）治疗大环内酯无反应肺炎支原体肺炎（MUMPP）患儿的疗效和安全性。方法：选取2013年1 - 12月在宝鸡市中心医院住院的流行性腮腺炎患儿173例为研究对象。根据大环内酯类药物初始治疗72小时后二级抗生素的选择，将患者分为PAZM组和SDXC组。比较两组患者的疗效和药物不良反应，分析难治性肺炎支原体肺炎（RMPP）的危险因素。结果：与PAZM组比较，SDXC组退热时间和止咳时间明显短于PAZM组，使用糖皮质激素的患者比例明显低于PAZM组，肺部病变吸收患者比例明显高于PAZM组。结论：SDXC治疗MUMPP患儿疗效优于PAZM组，短期使用多西环素相对安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国当代儿科杂志 Medicine-Pediatrics, Perinatology and Child Health

CiteScore

1.50

自引率

0.00%

发文量

5006

期刊介绍： The Chinese Journal of Contemporary Pediatrics (CJCP) is a peer-reviewed open access periodical in the field of pediatrics that is sponsored by the Central South University/Xiangya Hospital of Central South University and under the auspices of the Ministry of Education of China. It is cited as a source in the scientific and technological papers of Chinese journals, the Chinese Science Citation Database (CSCD), and is one of the core Chinese periodicals in the Peking University Library. CJCP has been indexed by MEDLINE/PubMed/PMC of the American National Library, American Chemical Abstracts (CA), Holland Medical Abstracts (EM), Western Pacific Region Index Medicus (WPRIM), Scopus and EBSCO. It is a monthly periodical published on the 15th of every month, and is distributed both at home and overseas. The Chinese series publication number is CN 43-1301/R；ISSN 1008-8830. The tenet of CJCP is to “reflect the latest advances and be open to the world”. The periodical reports the most recent advances in the contemporary pediatric field. The majority of the readership is pediatric doctors and researchers.